PlainPharmaWatch

CMS Open Payments · Program Year 2024

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. reported $11,481,371.75 in payments to 604 physicians and teaching hospitals across 1,476 transactions.

See the rankings → How this is sourced
$11.5M
Total payments
1,476
Transactions
604
Recipients
#152
of 1,925 companies

Iovance Biotherapeutics, Inc. reported $11,481,371.75 in payments to 604 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #152 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $19.0K per recipient across 4 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Iovance Biotherapeutics, Inc. pairs top-10% payment volume with a broadly spread payment pattern across many recipients.

#152
of 1,925 companies
0.1%
of all US industry payments
0.1%
paid to its single top recipient
4
payment categories

How Iovance Biotherapeutics, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Iovance Biotherapeutics, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$11,481,372 Top 8% higher than 92% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Iovance Biotherapeutics, Inc.

Averaging $7.8K per transaction and $19.0K per recipient, Iovance Biotherapeutics, Inc.'s Program Year 2024 total comes to $11,481,371.75 across 1,476 transactions and 604 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #152 of 1,925 companies, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.

12 transactions worth $40.0K make "Honoraria" the top general-payment category in the 4-category breakdown below, 0.3% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 4 types of general payments, Iovance Biotherapeutics, Inc.'s largest category was "Honoraria" at $40.0K - 0.3% of the company's reported total.

How Iovance Biotherapeutics, Inc. divides its payments

General-payment categories, ordered by reported total

1. Honoraria$40.0K2. Consulting Fee$33.8K3. Food and Beverage$26.7K4. Travel and Lodging$14.1K
Payment Type Amount Transactions
Honoraria $40.0K 12
Consulting Fee $33.8K 16
Food and Beverage $26.7K 524
Travel and Lodging $14.1K 52

Recipient Concentration in General Payments

The five largest recipient relationships account for $45,173.56 (39.4%) of $114,707.51 in this company's General Payments records across 411 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Iovance Biotherapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Joel Neal$13.9KAmanda Kirane$10.8KDavid Carbone$7.8KBenjamin Creelan$7.7KThach-Giao Truong$5.0K
  1. 1

    Joel Neal

    $13,875.00 across 9 reported transactions

  2. 2

    Amanda Kirane

    $10,812.26 across 18 reported transactions

  3. 3

    David Carbone

    $7,767.21 across 10 reported transactions

  4. 4

    Benjamin Creelan

    $7,749.19 across 10 reported transactions

  5. 5

    Thach-Giao Truong

    $4,969.90 across 9 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $7.8K. Average per recipient: $19.0K.

Total Amount

$11,481,371.75

Avg per Transaction

$7.8K

Avg per Recipient

$19.0K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Iovance Biotherapeutics, Inc. Share

0.1%

#152 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Iovance Biotherapeutics, Inc.

Phathom Pharmaceuticals, Inc.

$11.5M 93,370 recipients

Ocular Therapeutix, Inc.

$11.4M 4,194 recipients

IBSA Institut Biochimique SA

$11.4M 17 recipients

Tris Pharma Inc

$11.4M 23,649 recipients

Orthofix Medical, Inc.

$11.6M 12,682 recipients

Genmab A/S

$11.6M 1 recipients

Frequently Asked Questions

How much did Iovance Biotherapeutics, Inc. pay to physicians and hospitals in 2024? ▾
Iovance Biotherapeutics, Inc. made $11,481,371.75 in payments to physicians and hospitals in Program Year 2024, across 1,476 individual transactions. This represents 0.1% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Iovance Biotherapeutics, Inc.? ▾
Averaging $19.0K per recipient, Iovance Biotherapeutics, Inc.'s 2024 payments reached 604 physicians and teaching hospitals.
What types of payments did Iovance Biotherapeutics, Inc. make? ▾
4 categories of general payment make up Iovance Biotherapeutics, Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Honoraria" at $40.0K, representing 0.3% of the company's reported total.
How does Iovance Biotherapeutics, Inc. rank among pharmaceutical companies? ▾
By total payment amount, Iovance Biotherapeutics, Inc. sits at #152 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Iovance Biotherapeutics, Inc.? ▾
Iovance Biotherapeutics, Inc.'s 1,476 transactions to 604 recipients in 2024 averaged $7.8K per transaction.
Where does the payment data for Iovance Biotherapeutics, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Iovance Biotherapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.